Outcomes

Outcomes employers can measure.

Real-world results from HV Health members with Type 2 Diabetes and/or Prediabetes across employer populations (2023–2024).

Average HbA1c Reduction

-1.6%

from baseline

At 12 months · n = 3,412

Average Weight Loss

-7.8%

of body weight

At 12 months · n = 3,412

Members Achieving HbA1c < 7%

63%

reached target range

At 12 months · n = 2,756

Program Engagement

78%

Members active at 90 days

Across employer populations

Methodology

Outcomes reflect real-world data collected from HV Health members enrolled through employer-sponsored benefit programs between 2023 and 2024. Members included have a documented diagnosis of Type 2 Diabetes and/or Prediabetes.

HbA1c and weight metrics are reported at 12 months of continuous enrollment. The HbA1c < 7% cohort reflects members with a baseline HbA1c at or above 7%. Engagement is defined as member activity at the 90-day mark following enrollment.

Sample sizes (n) represent members with available follow-up data at the reported timepoint. Individual results vary; these figures represent cohort averages and should not be interpreted as a guarantee of individual outcomes.

Evidence

Built on real-world clinical and commercial performance

Our approach is continuously optimized using real-world patient outcomes and engagement data across multilingual populations.

10,000+

Patients supported

Unique individuals cared for through HolaVida Health

73%

Female patients

Reflecting the populations we serve

68%

Age 35–64

Working-age adults in their prime years

3+

Languages

English, Spanish, and Portuguese